Retatrutide
Description
Retatrutide is the latest innovation in metabolic peptides, known as the "Triple G" agonist. It acts simultaneously on three key hormone receptors: GLP-1 (appetite control), GIP (fat and sugar metabolism), and Glucagon (energy expenditure). This synergistic action makes it one of the most promising research tools for significant weight loss and comprehensive metabolic improvement.(1)
Presentation: 10mg lyophilized vial (Research dose).
Technical Specifications
- Name: Retatrutide (LY-3437943)
- Type: Triple Agonist of GLP-1 / GIP / Glucagon receptors
- Molecular Weight: ~4731.33 g/mol
- Appearance: White lyophilized powder
- Storage: Keep refrigerated (2-8°C). Protect from light.
Research & Scientific Literature
Retatrutide is a synthetic investigational peptide that acts as an agonist for three distinct hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple action differentiates it from predecessors like semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP).(1)
By activating the glucagon receptor, Retatrutide adds a new component: increased energy expenditure and lipid burning (thermogenesis), in addition to the appetite suppression and improved insulin sensitivity provided by GLP-1 and GIP agonists.(2)
Phase 2 clinical trials have shown impressive results. In a study published in the *New England Journal of Medicine*, participants with obesity who received the highest dose of Retatrutide achieved an average weight reduction of 24.2% after 48 weeks.(3) These results surpass those typically observed with other incretin agents approved to date, suggesting unprecedented potential for obesity management.
A notable secondary finding from Retatrutide studies is its impact on non-alcoholic fatty liver disease (NAFLD). In trials, a significant proportion of patients showed drastic reduction, and even normalization, of liver fat.(4) It is believed that glucagon receptor activation plays a key role in mobilizing fat from the liver, offering a potential therapy for this prevalent condition.
In addition to weight loss, Retatrutide has demonstrated substantial improvements in cardiometabolic markers. Studies indicate reductions in blood pressure, improvements in lipid profiles (cholesterol and triglycerides), and better blood glucose control (HbA1c) in patients with type 2 diabetes. Its triple mechanism addresses multiple pathways of metabolic dysfunction simultaneously.(3)
Research Disclaimer: The information regarding this compound is provided strictly for academic and scientific review. It is not intended for diagnostic, therapeutic, or clinical use in humans or animals. This is an investigational compound.
- Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism.
- Knerr, P. J., et al. (2022). Mechanisms of Action of the Triple Agonist Retatrutide.
- Jastreboff, A. M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.
- Loomba, R., et al. (2023). Retatrutide for the Treatment of Non-Alcoholic Fatty Liver Disease.
- Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet.